IRLAB Therapeutics AB (publ) (IRLAB-A.ST)

SEK 11.25

(0.0%)

Market Cap (In SEK)

582.62 Million

Revenue (In SEK)

5.67 Million

Net Income (In SEK)

-177.83 Million

Avg. Volume

31.02 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.6-20.2
PE
-
EPS
-
Beta Value
0.664
ISIN
SE0012675361
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Kristina Torfgard Ph.D.
Employee Count
-
Website
https://www.irlab.se
Ipo Date
2017-02-28
Details
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.